EA202192905A1 - Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли - Google Patents

Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли

Info

Publication number
EA202192905A1
EA202192905A1 EA202192905A EA202192905A EA202192905A1 EA 202192905 A1 EA202192905 A1 EA 202192905A1 EA 202192905 A EA202192905 A EA 202192905A EA 202192905 A EA202192905 A EA 202192905A EA 202192905 A1 EA202192905 A1 EA 202192905A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyridone
methyl
pharmaceutically acceptable
acceptable salts
compounds containing
Prior art date
Application number
EA202192905A
Other languages
English (en)
Inventor
Эндрю Вудленд
Марк Белл
Original Assignee
Юниверсити Оф Данди
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсити Оф Данди filed Critical Юниверсити Оф Данди
Publication of EA202192905A1 publication Critical patent/EA202192905A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Данное изобретение касается соединений, содержащих N-метил-2-пиридон, и фармацевтически приемлемых солей и композиций таких соединений. Такие соединения являются полезными в противовоспалительной и противораковой терапии. Поэтому настоящее изобретение также относится к таким соединениям для использования в качестве лекарственных средств, в частности для лечения воспалительных заболеваний и онкологии.
EA202192905A 2019-04-24 2020-04-22 Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли EA202192905A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1905721.5A GB201905721D0 (en) 2019-04-24 2019-04-24 Compounds
PCT/EP2020/061173 WO2020216779A1 (en) 2019-04-24 2020-04-22 Compounds comprising n-methyl-2-pyridone, and pharmaceutically acceptable salts

Publications (1)

Publication Number Publication Date
EA202192905A1 true EA202192905A1 (ru) 2022-02-17

Family

ID=66810205

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192905A EA202192905A1 (ru) 2019-04-24 2020-04-22 Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли

Country Status (14)

Country Link
US (1) US20220204500A1 (ru)
EP (1) EP3958976A1 (ru)
JP (1) JP2022530405A (ru)
KR (1) KR20220012250A (ru)
CN (1) CN113924298A (ru)
AU (1) AU2020263112A1 (ru)
BR (1) BR112021021284A2 (ru)
CA (1) CA3148317A1 (ru)
EA (1) EA202192905A1 (ru)
GB (2) GB201905721D0 (ru)
IL (1) IL287470B1 (ru)
MX (1) MX2021013014A (ru)
WO (1) WO2020216779A1 (ru)
ZA (1) ZA202109179B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
CN115667237A (zh) * 2020-07-17 2023-01-31 成都苑东生物制药股份有限公司 作为bet抑制剂的新型杂环化合物
GB202016977D0 (en) * 2020-10-26 2020-12-09 In4Derm Ltd Compounds
CN113582859A (zh) * 2021-06-28 2021-11-02 佳尔科生物科技南通有限公司 一种4-酚氧基-3-氨基苯甲醚的制备方法
IL309651A (en) 2021-06-29 2024-02-01 Tay Therapeutics Ltd History Pyrolopyridone is useful in the treatment of cancer
CN115611890A (zh) * 2021-07-15 2023-01-17 成都苑东生物制药股份有限公司 一种新型噻吩类bet溴结构域抑制剂、其制备方法及医药用途
WO2023081720A1 (en) * 2021-11-03 2023-05-11 Vyne Therapeutics Inc. Uses of pan bet inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2652304T3 (es) 2009-11-05 2018-02-01 Glaxosmithkline Llc Compuesto de benzodiacepina novedoso
EP2496582B1 (en) 2009-11-05 2016-01-27 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2014125408A2 (en) * 2013-02-12 2014-08-21 Aurigene Discovery Technologies Limited Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
SG11201510678TA (en) * 2013-06-28 2016-01-28 Abbvie Inc Bromodomain inhibitors
WO2015081246A1 (en) * 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015081280A1 (en) 2013-11-26 2015-06-04 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
WO2016139361A1 (en) * 2015-03-05 2016-09-09 Boehringer Ingelheim International Gmbh New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
DK3442972T3 (da) * 2016-04-15 2020-04-27 Abbvie Inc Bromdomænehæmmere
WO2018130174A1 (zh) 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
CN109384784B (zh) * 2017-08-10 2021-01-12 浙江海正药业股份有限公司 磺酰胺类衍生物、其制备方法及其在医药上的用途
CN109384785B (zh) * 2017-08-10 2021-09-28 浙江海正药业股份有限公司 吡咯并吡啶酮类衍生物、其制备方法及其在医药上的用途

Also Published As

Publication number Publication date
IL287470A (en) 2021-12-01
JP2022530405A (ja) 2022-06-29
IL287470B1 (en) 2024-02-01
WO2020216779A1 (en) 2020-10-29
KR20220012250A (ko) 2022-02-03
GB2597228B (en) 2022-11-30
EP3958976A1 (en) 2022-03-02
BR112021021284A2 (pt) 2022-01-18
US20220204500A1 (en) 2022-06-30
GB201905721D0 (en) 2019-06-05
GB2597228A (en) 2022-01-19
ZA202109179B (en) 2023-10-25
MX2021013014A (es) 2022-01-18
CA3148317A1 (en) 2020-10-29
GB202116739D0 (en) 2022-01-05
CN113924298A (zh) 2022-01-11
AU2020263112A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
EA201790088A1 (ru) Ингибиторы syk
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
PH12019501896A1 (en) Therapeutic dendrimers
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
PH12019500569A1 (en) Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
EA202092082A1 (ru) Соединения аминопиразиндиола как ингибиторы pi3k-
EA202090969A1 (ru) Третичные спирты в качестве ингибиторов pi3k-
EA201990763A1 (ru) Ингибиторы дофамин-в-гидроксилазы, проникающие через гематоэнцефалический барьер